Senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) set plans to file for regulatory approval of more than 10 new products between 2015 and 2019.
Article continues below
Each of them has the potential to exceed $1 billion in revenue, as well as more than 40 line extensions of existing and new medicines.
With a portfolio focused on five core therapeutic areas – Immunology, Infectious Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism and Oncology – the Pharmaceutical segment of Johnson & Johnson is delivering transformational new medicines for unmet medical needs worldwide.
Janssen has launched 14 new products since 2009, seven of which already exceed or are on track to achieve sales in excess of $1 billion during 2015.2 These new products, coupled with core growth brands, have fueled industry-leading sales growth and contributed significantly to the earnings growth of Johnson & Johnson.
The combined strength of Janssen’s in-market portfolio and robust near-term pipeline provides the momentum to sustain above-industry compound annual growth through 2019.
“In the past two years, our performance and growth rates have been industry-leading, and we look forward to continuing to drive above-industry growth with our current in-market portfolio and next wave of medicines,†said Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson.
“We are working with our partners to advance the innovative products in our pipeline and to deliver significant benefits to patients.â€
The total pharmaceutical market reached $1 trillion in 2014 with nearly 40 percent of the growth coming from specialty medicines, including oncology, autoimmune, respiratory and anti-viral medications.
Going forward, the total global branded pharmaceuticals market is expected to grow at a compound annual operational growth rate of approximately 3 percent from 2014 to 2019, according to IMS Health, the independent analysis and market research service that tracks the industry.
Among the top 10 global pharmaceutical companies, IMS Health also reports that the Pharmaceutical segment of Johnson & Johnson was among the fastest growing in the U.S., Europe and Japan in 2014, with sales of $32.3 billion, representing an operational increase of 16.5 percent3 versus 2013. ■